Evidence map›Paper›PMID 42807035›Full record

ArticleFrontiers in oncology2026

Case Report: Trastuzumab deruxtecan combined with fulvestrant in a patient with HR+/HER2-low metastatic breast cancer.

Jiaying Chai, Xinyi Zheng, Longyu Hu, Meiwen Ling, Jingjing Yang, Nana Yu, Chen Gan, Yang Sui, Ling Cheng, Huaidong Cheng

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiaying Chai *Department of Oncology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Xinyi Zheng *Department of Oncology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Longyu HuDepartment of Oncology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Meiwen LingDepartment of Oncology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Jingjing YangDepartment of Oncology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Nana YuDepartment of Oncology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Chen GanDepartment of Oncology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Yang SuiDepartment of Oncology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Ling ChengDepartment of Traditional Chinese Medicine, Shenzhen Pingshan People's Hospital, Shenzhen, China.
Huaidong ChengDepartment of Oncology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most common malignancy among women worldwide, and hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-low breast cancer poses significant challenges once resistance to endocrine therapy and CDK4/6 inhibitors develops. We present a 45-year-old female patient with HR+/HER2-low metastatic breast cancer who progressed on standard-of-care treatments. The combination of trastuzumab deruxtecan and fulvestrant demonstrated significant clinical efficacy and favorable tolerability, achieving a progression-free survival of 26 months with no grade 3 or higher adverse events observed. This case suggests that this combination may represent a promising therapeutic strategy for patients with advanced, treatment-refractory HR+/HER2-low breast cancer, offering a useful reference for clinical practice.

Indexed as

antibody-drug conjugatefulvestrantHER2-lowmetastatic breast cancertrastuzumab deruxtecan

Identifiers

PMID42807035
PMCPMC13616787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.